Caspofungin versus liposomal amphotericin B for empirical therapy.
Danaher
Patrick J
PJ
D000666:Amphotericin B / Q000191:economics / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000191:economics / Q000627:therapeutic use*; D000077336:Caspofungin; D054714:Echinocandins; D005334:Fever / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D055666:Lipopeptides; D008081:Liposomes; D009181:Mycoses / Q000188:drug therapy*; D009503:Neutropenia / Q000209:etiology; D010456:Peptides, Cyclic / Q000191:economics / Q000627:therapeutic use*; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use; D014230:Triazoles / Q000191:economics / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008081:Liposomes; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D000077336:Caspofungin; D065819:Voriconazole